| scholarly article | Q13442814 |
| P50 | author | Thomas Wisniewski | Q41043812 |
| P2093 | author name string | Domenico Praticò | |
| Jin Chu | |||
| P2860 | cites work | Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease | Q24298408 |
| TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity | Q24321405 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome | Q28217381 | ||
| Decreased expression of synapse-related genes and loss of synapses in major depressive disorder | Q28580177 | ||
| GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome | Q34177171 | ||
| Gamma secretase-activating protein is a substrate for caspase-3: implications for Alzheimer's disease | Q34714810 | ||
| Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles | Q34948311 | ||
| Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration | Q35683326 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach | Q35706615 | ||
| Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice | Q35750756 | ||
| 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease | Q36299503 | ||
| 100 years and counting: prospects for defeating Alzheimer's disease | Q36643419 | ||
| Regulation of gamma-secretase activity in Alzheimer's disease | Q36734828 | ||
| Mental retardation and associated neurological dysfunctions in Down syndrome: a consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways | Q36969504 | ||
| Inhibition and modulation of gamma-secretase for Alzheimer's disease | Q37215842 | ||
| Amyloid precursor protein processing and Alzheimer's disease | Q37860317 | ||
| Development and mechanism of γ-secretase modulators for Alzheimer's disease | Q38101383 | ||
| A fast growing spectrum of biological functions of γ-secretase in development and disease | Q38149886 | ||
| Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles | Q39012382 | ||
| Immunohistochemical characterization of γ-secretase activating protein expression in Alzheimer's disease brains. | Q49108254 | ||
| Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. | Q53441656 | ||
| Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis | Q78863050 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 138-143 | |
| P577 | publication date | 2015-10-08 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | GATA1-mediated transcriptional regulation of the γ-secretase activating protein increases Aβ formation in Down syndrome | |
| P478 | volume | 79 |
| Q37730984 | Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments |
| Q38661982 | Frontal Cortex and Hippocampal γ-Secretase Activating Protein Levels in Prodromal Alzheimer Disease |
| Q60197707 | GSAP modulates γ-secretase specificity by inducing conformational change in PS1 |
| Q64118047 | GSAP modulates γ-secretase specificity by inducing conformational change in PS1 |
Search more.